Home | Meeting coverage | UEG week virtual 2021

Most viewed UEG week 2021

UEG 2021

Peter Irving, MD

Where is the future in IBD treatment? P19, JAKi, S1P?

100 seconds

UEG 2021

F. Gomollón, P. Eder, S. Schreiber, P. Irving

Is STRIDE II already history?

UEG 2021

Silvio Danese, MD

UEG highlights: Vedolizumab in Chronic pouchitis; ...

100 seconds

UEG 2021

Stefan Schreiber, MD

IL-23: Risankizumab - effective maintenance, long carry...

100 seconds

UEG 2021

A. Dignaß, A. Magro, M. C. Fantini, S. Danese, S. Schreiber

What's the right target? JAK1 or JAK3 or TYK2?

post UEG Team Discussion

UEG 2021

Axel Dignaß, MD

STRIDE 2.0 - Treatment goals in IBD: Patient...

100 seconds

UEG 2021

Stefan Schreiber, MD

Single JAK targeting: JAK1 vs. JAK3

100 seconds

UEG 2021

F. Gomollón, P. Eder, S. Schreiber, P. Irving

Side Effects - Biologicals: News from UEGw

UEG 2021

Fernando Gomollón, MD

A panoramic view of UEG and IBD from Spain

100 seconds

UEG 2021

David Laharie, MD

How to significantly reduce the arterial vascular risk...

UEG 2021

Piotr Eder, Md, PhD

Discontinuation strategies: Data hint towards...

Spotlight Discussions – Targeting Efficacy

UEG 2021

G. Mantzaris, I. Dotan, M. Allez, A. Dignaß, S. Schreiber

Treatment targets: The impact of STRIDE II on our...

UEG 2021

A. Dignaß, F. Magro, M. C. Fantini, S. Danese, S. Schreiber

What do drug levels and antibody levels tell us?

post UEG Team Discussion

UEG 2021

A. Dignaß, A. Magro, M. C. Fantini, S. Danese, S. Schreiber

What's the right target? JAK1 or JAK3 or TYK2?

post UEG Team Discussion

UEG 2021

A. Dignaß, F. Gomollón, F. Magro, M.C. Fantini, S. Danese, S. Schreiber

Do we need IL-23 blockade? Are all inhibitors the same?

post UEG Team Discussion

UEG 2021

A. Dignaß, F. Gomollón, F. Magro, M.C. Fantini, S. Danese, S. Schreiber

Targeting S1P: effective, well tolerated, soon to be...

post UEG Team Discussion

UEG 2021

A. Dignaß, F.Magro, M. C. Fantini, S. Danese, S. Schreiber

Review JAK1 Inhibition: great speed of action,...

post UEG Team Discussion

UEG 2021

G. Mantzaris, I. Dotan, M. Allez, A. Dignaß

Do we need H2H trials? We need new endpoints, regaining...

Targeting Efficacy in 100 seconds – ENG

UEG 2021

Johan Burisch, MD

Dose escalation strategies to increase the efficacy of...

100 seconds

UEG 2021

Stefan Schreiber, MD

S1P targeting: very immediate effficacy and good safety...

100 seconds

UEG 2021

Silvio Danese, MD

UEG highlights: Vedolizumab in Chronic pouchitis; ...

100 seconds

UEG 2021

Fernando Magro, MD

Upadacitinib with rapid and effective control of...

100 seconds

UEG 2021

Stefan Schreiber, MD

Single JAK targeting: JAK1 vs. JAK3

100 seconds

UEG 2021

Fernando Magro, MD

Tofacitinib numerically increases Herp Zoster risk...

100 seconds

UEG 2021

Stefan Schreiber, MD

IL-23: Risankizumab - effective maintenance, long carry...

100 seconds

Targeting Efficacy in 100 seconds – ITA/ GER / DK

UEG 2021

Silvio Danese, MD

UEG highlights: Vedolizumab in Chronic pouchitis; ...

100 seconds

UEG 2021

Stefan Schreiber, MD

S1P Rezeptor Agonisten mit unmittelbarer Effektivität...

100 seconds

UEG 2021

Johan Burisch, MD

Dose escalation strategies to increase the efficacy of...

100 seconds

UEG 2021

Axel Dignaß, MD

Neue JAK-Therapieoptionen vor der Zulassung. Es wird...

100 seconds

UEG 2021

Stefan Schreiber, MD

JAK1 vs. JAK3 - was ist effektiver?

100 seconds

UEG 2021

Stefan Schreiber, MD

Risankizumab: Effektive Erhaltung mit Langzeiteffekt

100 seconds

Spotlight Discussions – Targeting Safety

UEG 2021

G. Mantzaris, I. Dotan, M. Allez, A. Dignaß, S. Schreiber

Immunosuppression and COVID: vaccination is effective,...

UEG 2021

F. Gomollón, P. Eder, S. Schreiber

Side Effects - Oral Therapies: News from UEGw

UEG 2021

F. Gomollón, P. Eder, S. Schreiber, P. Irving

Side Effects - Biologicals: News from UEGw

Targeting Safety in 100 seconds – ENG

UEG 2021

Johan Burisch, MD

Protein profiling as efficacy predictor of infliximab...

100 seconds

UEG 2021

David Laharie, MD

How to significantly reduce the arterial vascular risk...

100 seconds

UEG 2021

Piotr Eder, MD, PhD

Safety of Ustekinumab in elderly patients - no...

100 seconds

Targeting Safety in 100 seconds – POL/FRA/DEN

UEG 2021

Johan Burisch, MD

Protein profiling as efficacy predictor of infliximab...

100 seconds

ACR 2021

Piotr Eder, MD, PhD

IBD w wieku podeszłym - czy można bezpiecznie stosować...

100 seconds

UEG 2021

David Laharie, MD

Comment réduire le risque cardio-vasculaire associé aux...

100 seconds

Spotlight Discussions – Therapy concepts

UEG 2021

G. Mantzaris, I. Dotan, M. Allez, A. Dignaß

Disease Clearance in UC: How can we translate this into...

UEG 2021

F. Gomollón, P. Eder, S. Schreiber, P. Irving

What ist the most exciting new drug on the horizon?...

UEG 2021

G. Mantzaris, I. Dotan, M. Allez, A. Dignaß

Microbiome, nutrition and life style: The effect on...

UEG 2021

F. Gomollón, P. Eder, S. Schreiber, P. Irving

Is STRIDE II already history?

UEG 2021

A. Dignaß, F. Gomollón, F. Magro, M.C. Fantini, S. Danese, S. Schreiber

Disease clearance? Treat to target still correct?

post UEG Team Discussion

Therapy Concepts in 100 Seconds – ENG

UEG 2021

David Laharie, MD

Do not stop infliximab in patients in complete...

100 seconds

UEG 2021

Massimo Claudio Fantini, MD, PhD

SEAVUE PK update: Immunogenicity of Ustekinumab vs...

100 seconds

UEG 2021

Fernando Magro, MD

Risankizumab: 12 weeks induction in patients wo initial...

100 seconds

UEG 2021

Piotr Eder, Md, PhD

Discontinuation strategies: Data hint towards...

100 seconds

UEG 2021

Fernando Magro, MD

PK SEAVUE Study: high proportion of patients with...

100 seconds

Therapy Concepts in 100 Seconds – POL/ITA/FRA

UEG 2021

David Laharie, MD

Mieux vaut ne pas arrêter l’infliximab dans la maladie...

100 seconds

UEG 2021

Piot Eder, MD, PhD

Czy warto kończyć terapię IFX w przypadku głębokiej...

100 seconds

UEG 2021

Massimo Claudio Fantini, MD, PhD

Ustekinumab e Adalimumab: farmacocinetica e...

100 seconds

Treatment goals in 100 Seconds – ENG

UEG 2021

Axel Dignaß, MD

Disease Clearance the future therapeutic goal...

100 seconds

UEG 2021

Axel Dignaß, MD

STRIDE 2.0 - Treatment goals in IBD: Patient...

100 seconds

UEG 2021

Massimo Claudio Fantini, MD, PhD

JAK inhibitors showing quick response in PRO...

100 seconds

Treatment goals in 100 Seconds – GER/ITA

UEG 2021

Axel Dignaß, MD

Therapieziele: Disease Clearance bei der Colitis...

100 seconds

UEG 2021

Axel Dignaß, MD

Therapieziele - STRIDE 2.0: Die Patientenperspektive,...

100 seconds

UEG 2021

Massimo Claudio Fantini, MD, PhD

JAK inhibitors e rapidità nel miglioramento dei PROs: i...

100 seconds

New treatment concepts in 100 seconds – ENG

UEG 2021

Peter Irving, MD

Vedolizumab effective in resistant pouchitis

100 seconds

UEG 2021

Silvio Danese, MD

UEG highlights: Vedolizumab in Chronic pouchitis; ...

100 seconds

UEG 2021

Massimo Claudio Fantini, MD, PhD

Ritlecitinib & Brepocitinib good remission rates and...

100 seconds

UEG 2021

Axel Dignaß, MD

New treatment options about to be approved. Treatment...

100 seconds

UEG 2021

Axel Dignaß, MD

New treatment options: IL23 modulators Risankizumab and...

100 seconds

New treatment concepts in 100 seconds – GER/ITA

UEG 2021

Silvio Danese, MD

UEG highlights: Vedolizumab in Chronic pouchitis; ...

100 seconds

UEG 2021

Axel Dignaß. MD

Neue Therapieoptionen: IL23 Modulation durch...

100 seconds

UEG 2021

Massimo Claudio Fantini, MD, PhD

Ritlecitinib e Prebocitinib i nuovi arrivati nel mondo...

UEG Week in 100 seconds – ENG

UEG 2021

Peter Irving, MD

Where is the future in IBD treatment? P19, JAKi, S1P?

100 seconds

UEG 2021

Silvio Danese, MD

UEG highlights: Vedolizumab in Chronic pouchitis; ...

100 seconds

UEG 2021

Johan Burisch, MD

No assocation between COVID outcome and IBD therapy

100 seconds

UEG 2021

Fernando Gomollón, MD

Spanish IBD contributions to UEGW: more and more...

100 seconds

UEG 2021

Fernando Gomollón, MD

A panoramic view of UEG and IBD from Spain

100 seconds

UEG Week in 100 seconds – ESP/ITA/DEN

UEG 2021

Fernando Gomollón, MD

Aportación española a la UEGW en EII: más y mejor

100 seconds

UEG 2021

Silvio Danese, MD

UEG highlights: Vedolizumab in Chronic pouchitis; ...

100 seconds

UEG 2021

Fernando Gomollón, MD

Un visión panorámica de la UEG y la EII desde España

100 seconds

UEG 2021

Johan Burisch, MD

No assocation between COVID outcome and IBD therapy

100 seconds